By targeting CD206, researchers aim to modulate TAM activity, reprogramming them from a pro-tumoral M2-like phenotype to an anti-tumoral M1-like phenotype, thus enhancing anti-tumor immune responses [82,83]. The gene discussed is MRC1; the disease is neoplasm.